Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients

International Journal of Cardiology

Volumn 158, Issue 3, 2012, Pages 376-379

  Egede, Rasmus ^a   Jensen, Lisette Okkels ^a   Hansen, Henrik Steen ^a   Antonsen, Lisbeth ^a   Hansen, Knud Norregaard ^a   Junker, Anders ^a   Thayssen, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

B mode ultrasound; Brachial artery; Endothelial function; Rosuvastatin treatment; STEMI patients

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; B SCAN; BLOOD VESSEL PARAMETERS; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FLOW MEDIATED DILATATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR ENDOTHELIUM;

AGED; BRACHIAL ARTERY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PYRIMIDINES; RISK FACTORS; SULFONAMIDES; TRIGLYCERIDES; VASODILATION;

EID: 84863628433     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.071     Document Type: Article

References (21)

1. J.E. Deanfield, J.P. Halcox, and T.J. Rabelink Endothelial function and dysfunction: testing and clinical relevance Circulation 115 2007 1285 1295
2. S. Moncada, and A. Higgs The l-arginine-nitric oxide pathway N Engl J Med 329 1993 2002 2012
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
5. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 39 43
6. J. Martinez-Gonzalez, B. Raposo, C. Rodriguez, and L. Badimon 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation Arterioscler Thromb Vasc Biol 21 2001 804 809
7. M. Romano, A. Mezzetti, and C. Marulli Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide J Investig Med 48 2000 183 189
8. L.O. Jensen, P. Thayssen, K.E. Pedersen, and T. Haghfelt Short- and long-term influence of diet and simvastatin on brachial artery endothelial function Int J Cardiol 107 2006 101 106
9. M.A. Ostad, S. Eggeling, and P. Tschentscher Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study Atherosclerosis 205 2009 227 232
10. T.M. Lu, Y.A. Ding, H.B. Leu, W.H. Yin, W.H. Sheu, and K.M. Chu Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia Am J Cardiol 94 2004 157 161
11. P. Gounari, D. Tousoulis, and C. Antoniades Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering Int J Cardiol 142 2010 87 91
12. R. Rawlings, A. Nohria, and P.Y. Liu Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event Am J Cardiol 103 2009 437 441
13. M. Pirro, G. Schillaci, and P.F. Romagno Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function J Cardiovasc Pharmacol Ther 14 2009 14 21
14. E. ter Avest, E.J. Abbink, S. Holewijn, J. de Graaf, C.J. Tack, and A.F. Stalenhoef Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH) Curr Med Res Opin 21 2005 1469 1476
15. A. Bellia, S. Rizza, and A. Galli Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes Atherosclerosis 210 2010 199 201
16. M.C. Corretti, T.J. Anderson, and E.J. Benjamin Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2002 257 265
17. K.E. Sorensen, D.S. Celermajer, and D.J. Spiegelhalter Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility Br Heart J 74 1995 247 253
18. M.L. Bots, J. Westerink, T.J. Rabelink, and E.J. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur Heart J 26 2005 363 368
19. K. Sakabe, N. Fukuda, K. Wakayama, T. Nada, H. Shinohara, and Y. Tamura Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients Int J Cardiol 94 2004 111 117
20. J. Dupuis, J.C. Tardif, and J.L. Rouleau Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial) Am J Cardiol 96 2005 1207 1213
21. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2